• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

40.17 -0.09 (-0.22%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 Next >
News headline image
Royalty Pharma Announces Dividend Increase
January 09, 2026
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
December 29, 2025
Royalty Pharma will now own 100% of the 8% to 16% Evrysdi royalty following multiple transactions with PTC since 2020 
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
December 16, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
December 04, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
December 04, 2025
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Royalty Pharma to Present at Upcoming Investor Conferences
November 26, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Reports Third Quarter 2025 Results
November 05, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
November 04, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Declares Fourth Quarter 2025 Dividend
October 17, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025
October 09, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director
September 29, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum
September 19, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation
September 11, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market
September 10, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
September 04, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes
September 02, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million
September 02, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
September 02, 2025
From Zenas BioPharma
Via GlobeNewswire
News headline image
Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million
August 25, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors
August 13, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Reports Second Quarter 2025 Results
August 06, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Declares Third Quarter 2025 Dividend
July 18, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors
July 17, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025
July 16, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion
June 24, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
June 04, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Completes the Acquisition of Its External Manager
May 16, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Present at Upcoming Investor Conferences
May 13, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition
May 12, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Reports First Quarter 2025 Results
May 08, 2025
From Royalty Pharma plc
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap